Table S4. Summary of significant differences in the reporting of all grades and severe (CTCAE: grade≥3) all-causality adverse events between days 0–90 from first ⁹⁰Y-RE procedure in patients with at least grade 2 baseline laboratory parameters compared with those with none or only mild changes in baseline laboratory parameters.

Parameter	System organ, class CTCAE grade	Baseline grade ≥2, n (%)			Baseline grade ≤1, n (%)		P value for all grades†	P value for grade ≥3‡
		All grades	Grade ≥3		all grades	Grade ≥3
Baseline albumin, grade ≤1 (n=519)grade ≥2 (n=72)	Total patients	351 (67.6)	85 (16.4)		48 (66.7)	24 (33.3)	0.894	0.001
	Nausea	148 (28.5)	6 (1.2)		11 (15.3)	0	0.016	1.000
	Constitutional	236 (45.5)	25 (4.8)		30 (41.7)	8 (11.1)	0.614	0.048
	Hepatobiliary	56 (10.8)	24 (4.6)		22 (30.6)	10 (13.9)	<0.001	0.005
	Hyperbilirubinemia	34 (6.6)	10 (1.9)		19 (26.4)	7 (9.7)	<0.001	0.002
	Respiratory	18 (3.5)	0		3 (4.2)	2 (2.8)	0.733	0.015
Baseline ALP, grade ≤1 (n=493), grade ≥2 (n=99)	Total patients	329 (66.7)	84 (17.0)		70 (70.7)	24 (24.2)	0.482	0.116
	Peripheral edema	1 (0.2)	0		2 (2.0)	2 (2.0)	0.074	0.028
	Hepatobiliary	49 (9.9)	21 (4.3)		29 (29.3)	12 (12.1)	<0.001	0.006
	Hyperbilirubinemia	27 (5.5)	8 (1.6)		26 (26.3)	9 (9.1)	<0.001	<0.001
	Hepatic failure	1 (0.2)	0		3 (3.0)	2 (2.0)	0.016	0.028
Baseline hemoglobin, grade ≤1 (n=536), grade ≥2 (n=58)	Total patients	360 (67.2)	96 (17.9)		38 (65.5)	13 (22.4)	0.883	0.377
	Abdominal distension	11 (2.1)	1 (0.2)		5 (8.6)	1 (1.7)	0.014	0.186
	Flatulence	3 (0.6)	0		3 (5.2)	0	0.014	NA
	Hyperbilirubinemia	45 (8.4)	13 (2.4)		9 (15.5)	5 (8.6)	0.089	0.024

This table reports the highest grade of adverse event reported by each patient within each time interval. ^†, P value across all grades; ^‡, P value for grades ≥3; NA, not applicable; REILD, radioembolization-induced liver disease; ALT, alanine transaminase; AST, aspartate aminotransferase; CTCAEs, Common Terminology Criteria Adverse Events; RE, radioembolization.